The highest risk of treatment failure is seen in patients previously infected with a resistant pathogen.

Sulopenem has in vitro activity against isolates of Neisseria gonorrhoeae non-susceptible to quinolones, azithromycin or β-lactams.

DUBLIN, Ireland and CHICAGO, April 11, 2019 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc, (Nasdaq: ITRM) a clinical-stage pharmaceutical company developing anti-infectives against multi-drug resistant pathogens, will present three posters at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Amsterdam, Netherlands on April 15, 2019.

“The rapidly rising rates of antibacterial resistance in pathogens associated with uncomplicated urinary tract infections are making successful treatment more challenging for physicians while patients are experiencing more significant clinical consequences. The elderly and those with diabetes mellitus are especially at risk for treatment failure and need better diagnostic and therapeutic options for this disease. As with urinary tract infections, the prevalence of resistant gonorrhoeae infections is also on the rise. We believe sulopenem, which is being developed in oral and intravenous formulations, has considerable potential as an important new treatment option to help patients and physicians better address infections caused by resistant pathogens.”

Michael Dunne, M.D., Chief Scientific Officer of Iterum Therapeutics

Poster Presentation p1656. Session: Urinary tract infections. 12:30 - 1:30PM CET

A patient-specific clinical predictive model to anticipate the risk of treatment failure in uncomplicated urinary tract infections

The authors reviewed the records of 4,792 patients given oral antibiotics for uncomplicated urinary tract infections (uUTIs) and assessed the difference in 28-day outcomes for patients with a uUTI whose pathogens were susceptible to empiric therapy versus those who were non-susceptible to therapy, highlighting the risk factors associated with failure. They concluded:

• The most significant risk for treatment failure is treatment of the index infection with an antibiotic to which the organism in a prior infection was resistant.
• Age, gender and diabetes mellitus also increased the likelihood of treatment failure.
• Treatment failure and hospitalization rates double with mismatched empiric antibiotic therapy.
• The more antibiotic class resistance, the higher likelihood of treatment failure.

Poster Presentation p1705. Session: Sexually transmitted infections complicated by antimicrobial resistance. 12:30 -1:30PM CET.

In vitro activity of Sulopenem against resistant Neisseria gonorrhoeae volunteers

• Sulopenem demonstrated in vitro activity against isolates of N. gonorrhoeae non-susceptible to ceftriaxone and cefixime, as well as those resistant to azithromycin or ciprofloxacin.

Poster Presentation p1992. Session: Evaluation of diverse antimicrobials in vitro and experimental models. 1:30PM - 2:30PM CET.

Post-antibiotic and sub-inhibitory minimum inhibitory concentration effects of Sulopenem

• Sulopenem exhibited a post antibiotic-subMIC effect, which potentially reflects additional antibacterial activity due to exposure of the bacteria to higher concentrations of drug.
• Sulopenem may be active for a longer period of the dosing interval than is defined simply by the amount of time the bacteria is exposed to drug levels at the mean inhibitory concentration.

The three posters will be available for review on Monday, April 15, 2019.